vs
Cellectis S.A.（CLLS）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
Maase Inc.的季度营收约是Cellectis S.A.的1.0倍（$9.9M vs $9.5M），Cellectis S.A.自由现金流更多（$27.6M vs $-18.3M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
CLLS vs MAAS — 直观对比
营收规模更大
MAAS
是对方的1.0倍
$9.5M
自由现金流更多
CLLS
多$45.9M
$-18.3M
损益表 — Q2 FY2024 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $9.9M |
| 净利润 | $-25.3M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -181.1% | -55.9% |
| 净利率 | -265.9% | — |
| 营收同比 | 375.0% | — |
| 净利润同比 | -51.9% | — |
| 每股收益（稀释后） | $-0.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSMAAS
| Q2 24 | $9.5M | — | ||
| Q3 23 | $1.6M | — | ||
| Q2 23 | $2.0M | — | ||
| Q4 22 | — | $9.9M | ||
| Q2 22 | $2.7M | — |
净利润CLLSMAAS
| Q2 24 | $-25.3M | — | ||
| Q3 23 | $-17.5M | — | ||
| Q2 23 | $-16.6M | — | ||
| Q4 22 | — | — | ||
| Q2 22 | $-19.5M | — |
毛利率CLLSMAAS
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 97.3% | — | ||
| Q4 22 | — | 78.7% | ||
| Q2 22 | 87.9% | — |
营业利润率CLLSMAAS
| Q2 24 | -181.1% | — | ||
| Q3 23 | -1258.1% | — | ||
| Q2 23 | -1180.5% | — | ||
| Q4 22 | — | -55.9% | ||
| Q2 22 | -1003.0% | — |
净利率CLLSMAAS
| Q2 24 | -265.9% | — | ||
| Q3 23 | -1064.1% | — | ||
| Q2 23 | -831.6% | — | ||
| Q4 22 | — | — | ||
| Q2 22 | -714.4% | — |
每股收益（稀释后）CLLSMAAS
| Q2 24 | $-0.28 | — | ||
| Q3 23 | $-0.31 | — | ||
| Q2 23 | $-0.20 | — | ||
| Q4 22 | — | — | ||
| Q2 22 | $-0.42 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $31.6M |
| 总资产 | $407.1M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSMAAS
| Q2 24 | $149.0M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $84.4M | — | ||
| Q4 22 | — | $10.9M | ||
| Q2 22 | $129.4M | — |
股东权益CLLSMAAS
| Q2 24 | $148.6M | — | ||
| Q3 23 | $76.1M | — | ||
| Q2 23 | $96.6M | — | ||
| Q4 22 | — | $31.6M | ||
| Q2 22 | $180.5M | — |
总资产CLLSMAAS
| Q2 24 | $407.1M | — | ||
| Q3 23 | $209.7M | — | ||
| Q2 23 | $227.7M | — | ||
| Q4 22 | — | $47.0M | ||
| Q2 22 | $320.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $-18.3M |
| 自由现金流率自由现金流/营收 | 290.5% | -184.4% |
| 资本支出强度资本支出/营收 | 13.2% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLLSMAAS
| Q2 24 | $28.9M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.4M | — | ||
| Q4 22 | — | $-18.2M | ||
| Q2 22 | $-60.2M | — |
自由现金流CLLSMAAS
| Q2 24 | $27.6M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.9M | — | ||
| Q4 22 | — | $-18.3M | ||
| Q2 22 | $-61.7M | — |
自由现金流率CLLSMAAS
| Q2 24 | 290.5% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -2391.4% | — | ||
| Q4 22 | — | -184.4% | ||
| Q2 22 | -2266.7% | — |
资本支出强度CLLSMAAS
| Q2 24 | 13.2% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 24.1% | — | ||
| Q4 22 | — | 1.0% | ||
| Q2 22 | 56.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
